Last edition
News about "Vijay Yajnik"
ENTYVIO Trial Shows Disease Clearance Benefits in Ulcerative Colitis
The first Ulcerative Colitis treat-to-target trial shows ENTYVIO (vedolizumab) delays disease-related complications with disease clearance versus symptomatic remission.
Vijay Yajnik | 22/10/2026 | By News Bureau | 134
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members